Regional distribution and metabolic effect of PCSK9 insLEU and R46L gene mutations and apoE genotype

Canadian Journal of Cardiology

Volumn 29, Issue 8, 2013, Pages 927-933

  Awan, Zuhier ^a   Delvin, Edgard E ^b   Levy, Emile ^b   Genest, Jacques ^c   Davignon, Jean ^a   Seidah, Nabil G ^a   Baass, Alexis ^a,c  

^a CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^b UNIVERSITY OF MONTREAL   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; APOLIPOPROTEIN A; APOLIPOPROTEIN B; APOLIPOPROTEIN E; C REACTIVE PROTEIN; FATTY ACID; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; KEXIN; LEPTIN; LEUCINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 GENE; R46L GENE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADOLESCENT; ARTICLE; BODY MASS; CANADA; CHILD; CHOLESTEROL BLOOD LEVEL; FATTY ACID BLOOD LEVEL; FEMALE; FRANCE; GENE INSERTION; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC SCREENING; GENOTYPE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID METABOLISM; LOSS OF FUNCTION MUTATION; MALE; NORMAL HUMAN; PHENOTYPE; SCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM; TRIACYLGLYCEROL BLOOD LEVEL;

ADOLESCENT; APOLIPOPROTEINS E; CANADA; CHILD; FEMALE; FRANCE; GENOTYPE; HUMANS; INSULIN; INSULIN RESISTANCE; LEPTIN; LIPIDS; MALE; MUTATION; PHENOTYPE; POLYMORPHISM, GENETIC; PROPROTEIN CONVERTASES; RISK FACTORS; SEQUENCE ANALYSIS, DNA; SERINE ENDOPEPTIDASES;

EID: 84881000753     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2013.03.004     Document Type: Article

References (44)

1. Seidah N.G., Benjannet S., Wickham L., et al. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci U S A 2003, 100:928-933.
2. Seidah N.G., Prat A. The proprotein convertases are potential targets in the treatment of dyslipidemia. JMol Med 2007, 85:685-696.
3. Zhang D.W., Lagace T.A., Garuti R., et al. Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation. JBiol Chem 2007, 282:18602-18612.
4. Kwon H.J., Lagace T.A., McNutt M.C., et al. Molecular basis for LDL receptor recognition by PCSK9. Proc Natl Acad Sci U S A 2008, 105:1820-1825.
5. Nassoury N., Blasiole D.A., Tebon Oler A., et al. The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR. Traffic 2007, 8:718-732.
6. Abifadel M., Varret M., Rabès J.P., et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003, 34:154-156.
7. Cohen J., Pertsemlidis A., Kotowski I.K., et al. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet 2005, 37:161-165.
8. Zhao Z., Tuakli-Wosornu Y., Lagace T.A., et al. Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am J Hum Genet 2006, 79:514-523.
9. Mayne J., Raymond A., Chaplin A., et al. Plasma PCSK9 levels correlate with cholesterol in men but not in women. Biochem Biophys Res Commun 2007, 361:451-456.
10. Cohen J.C., Boerwinkle E., Mosley T.H., et al. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. NEngl J Med 2006, 354:1264-1272.
11. Kathiresan S. APCSK9 missense variant associated with a reduced risk of early-onset myocardial infarction. NEngl J Med 2008, 358:2299-2300.
12. Davignon J., Dubuc G., Seidah N.G. The influence of PCSK9 polymorphisms on serum low-density lipoprotein cholesterol and risk of atherosclerosis. Curr Atheroscler Rep 2010, 12:308-315.
13. Yue P., Averna M., Lin X., et al. The c.43_44insCTG variation in PCSK9 is associated with low plasma LDL-cholesterol in a Caucasian population. Hum Mutat 2006, 27:460-466.
14. Fasano T., Cefalù A.B., Di Leo E., et al. Anovel loss of function mutation of PCSK9 gene in white subjects with low-plasma low-density lipoprotein cholesterol. Arterioscler Thromb Vasc Biol 2007, 27:677-681.
15. Chen S.N., Ballantyne C.M., Gotto A.M., et al. Acommon PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis. JAm Coll Cardiol 2005, 45:1611-1619.
16. Abifadel M., Rabès J.P., Jambart S., et al. The molecular basis of familial hypercholesterolemia in Lebanon: spectrum of LDLR mutations and role of PCSK9 as a modifier gene. Hum Mutat 2009, 30:682-691.
17. Abifadel M., Bernier L., Dubuc G., et al. APCSK9 variant and familial combined hyperlipidaemia. JMed Genet 2008, 45:780-786.
18. Miyake Y., Kimura R., Kokubo Y., et al. Genetic variants in PCSK9 in the Japanese population: rare genetic variants in PCSK9 might collectively contribute to plasma LDL cholesterol levels in the general population. Atherosclerosis 2008, 196:29-36.
19. Stein E.A., Gipe D., Bergeron J., et al. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet 2012, 380:29-36.
20. Paradis G., Lambert M., O'Loughlin J., et al. The Québec Child and Adolescent Health and Social Survey: design and methods of a cardiovascular risk factor survey for youth. Can J Cardiol 2003, 19:523-531.
21. Allard P., Delvin E.E., Paradis G., et al. Distribution of fasting plasma insulin, free fatty acids, and glucose concentrations and of homeostasis model assessment of insulin resistance in a representative sample of Quebec children and adolescents. Clin Chem 2003, 49:644-649.
22. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972, 18:499-502.
23. Punthakee Z., Delvin E.E., O'Loughlin J., et al. Adiponectin, adiposity, and insulin resistance in children and adolescents. JClin Endocrinol Metab 2006, 91:2119-2125.
24. Main B.F., Jones P.J., MacGillivray R.T., et al. Apolipoprotein E genotyping using the polymerase chain reaction and allele-specific oligonucleotide primers. JLipid Res 1991, 32:183-187.
25. Zivelin A., Rosenberg N., Peretz H., et al. Improved method for genotyping apolipoprotein E polymorphisms by a PCR-based assay simultaneously utilizing two distinct restriction enzymes. Clin Chem 1997, 43:1657-1659.
26. Matthews D.R., Hosker J.P., Rudenski A.S., et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
27. Baass A., Dubuc G., Tremblay M., et al. Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents. Clin Chem 2009, 55:1637-1645.
28. Dubuc G., Tremblay M., Paré G., et al. Anew method for measurement of total plasma PCSK9: clinical applications. JLipid Res 2010, 51:140-149.
29. Awan Z., Seidah N.G., MacFadyen J.G., et al. Rosuvastatin, proprotein convertase subtilisin/kexin type 9 concentrations, and LDL cholesterol response: the JUPITER trial. Clin Chem 2012, 58:183-189.
30. Laberge A.M., Michaud J., Richter A., et al. Population history and its impact on medical genetics in Quebec. Clin Genet 2005, 68:287-301.
31. Bétard C., Kessling A.M., Roy M., et al. Molecular genetic evidence for a founder effect in familial hypercholesterolemia among French Canadians. Hum Genet 1992, 88:529-536.
32. Vohl M.C., Moorjani S., Roy M., et al. Geographic distribution of French-Canadian low-density lipoprotein receptor gene mutations in the Province of Quebec. Clin Genet 1997, 52:1-6.
33. Mayne J., Dewpura T., Raymond A., et al. Novel loss-of-function PCSK9 variant is associated with low plasma LDL cholesterol in a French-Canadian family and with impaired processing and secretion in cell culture. Clin Chem 2011, 57:1415-1423.
34. Huijgen R., Fouchier S.W., Denoun M., et al. Plasma levels of PCSK9 and phenotypic variability in familial hypercholesterolemia. JLipid Res 2012, 53:979-983.
35. Scartezini M., Hubbart C., Whittall R.A., et al. ThePCSK9 gene R46L variant is associated with lower plasma lipid levels and cardiovascular risk in healthy U.K. men. Clin Sci 2007, 113:435-441.
36. Humphries S.E., Neely R.D., Whittall R.A., et al. Healthy individuals carrying the PCSK9 p.R46L variant and familial hypercholesterolemia patients carrying PCSK9 p.D374Y exhibit lower plasma concentrations of PCSK9. Clin Chem 2009, 55:2153-2161.
37. Pisciotta L., Sallo R., Rabacchi C., et al. Leucine 10 allelic variant in signal peptide of PCSK9 increases the LDL cholesterol-lowering effect of statins in patients with familial hypercholesterolaemia. Nutr Metab Cardiovasc Dis 2012, 22:831-835.
38. Sing C.F., Davignon J. Role of the apolipoprotein E polymorphism in determining normal plasma lipid and lipoprotein variation. Am J Hum Genet 1985, 37:268-285.
39. Eto M., Watanabe K., Ishii K. Reciprocal effects of apolipoprotein E alleles (epsilon 2 and epsilon 4) on plasma lipid levels in normolipidemic subjects. Clin Genet 1986, 29:477-484.
40. Wilson P.W. Relation of high-density lipoprotein subfractions and apolipoprotein E isoforms to coronary disease. Clin Chem 1995, 41:165-169.
41. Xhignesse M., Lussier-Cacan S., Sing C.F., et al. Influences of common variants of apolipoprotein E on measures of lipid metabolism in a sample selected for health. Arterioscler Thromb 1991, 11:1100-1110.
42. Marduel M., Ouguerram K., Serre V., et al. Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation. Hum Mutat 2013, 34:83-87.
43. Dallongeville J., Lussier-Cacan S., Davignon J. Modulation of plasma triglyceride levels by apoE phenotype: a meta-analysis. JLipid Res 1992, 33:447-454.
44. Pascoe J., Hollern D., Stamateris R., et al. Free fatty acids block glucose-induced β-cell proliferation in mice by inducing cell cycle inhibitors p16 and p18. Diabetes 2012, 61:632-641.